Investigating the heart-protective effects of early Dapagliflozin in heart attack patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical investigation focuses on the early administration of Dapagliflozin (DAPA) in patients experiencing acute myocardial infarction (AMI) to assess its cardioprotective effects. The study aims to determine whether DAPA can reduce infarct size and mitigate myocardial damage related to reperfusion injury when given before percutaneous coronary intervention (pPCI). Participants will receive DAPA or a placebo, and their cardiac biomarkers will be monitored over a three-month follow-up period to evaluate the drug's effectiveness in preventing heart failure and acute kidney injury. The study is particularly relevant as DAPA has been approved for heart failure but lacks sufficient data on its impact in AMI cases.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients with ST-elevation myocardial infarction (STEMI).
2. STEMI was defined according to the Fourth Universal Definition of AMI.
3. 18 - 80 years of age.
4. Diabetics or non-diabetics.
5. eGFR \> 45 ml/min/1.73m2.
6. Blood pressure before first drug dosing \>110/70 mmHg.

Exclusion Criteria:

1. Cardiogenic shock.
2. Hypoglycemia.
3. History of diabetic ketoacidosis.
4. Genital and urinary infections.
5. History of AMI.
6. Stent thrombosis.
7. Previous coronary artery bypass surgery.
8. Severe hepatic insufficiency.
9. Advanced cancer patients.
10. Blood pH \< 7.32.
11. Known allergy to SGLT-2 inhibitors.
12. Hemodynamic instability.
13. Females of childbearing potential without adequate contraceptive methods.
14. Patients currently on or have received any SGLT-2 inhibitors.

Where it's running

• Mohammad Soliman
  Shibīn al Kawm, Menofia, Egypt Recruiting

Study contacts

• Study coordinator: Mohammad Soliman
• Email: dr.mhtantawy@gmail.com
• Phone: +201003474565

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Heart@Home: Safe, at-home care for people with acute heart problems compared with hospital care

  This trial tests whether hospital-level care at home can safely and effectively treat adults with acute heart conditions who would normally be in the hospital.

  Recruiting Tel-Aviv Sourasky Medical Center · Tel Aviv · NCT07913152

• Digital cardiac rehab to help heart attack patients improve function

  A digital health–supported cardiac rehabilitation program is being tested to see if it helps people after a heart attack improve fitness and stay engaged with rehab, compared with standard outpatient rehab.

  Recruiting Cairo University · Minya, Minya Province · NCT07867197

• NMR-based Risk Test and Digital Health Support for midlife adults in Eloisa

  This study tests whether an NMR metabolomics risk test can guide tailored digital health programs for midlife adults at risk of diabetes, heart disease, stroke, kidney disease, or fatty liver.

  Recruiting University of Eastern Finland · Savonlinna · NCT07820800

• See if stopping long-term aspirin is as good as continuing it in older adults with stable ischemic heart disease

  In adults 65 and older with stable ischemic heart disease, this trial tests whether stopping daily low-dose aspirin is not worse than continuing it.

  Recruiting at 2 sites Phase 4 Odense University Hospital · Copenhagen and 1 other locations · NCT07795398

• Innate Immune Cells and Early Fibrotic Repair After a Heart Attack

  This study tests whether specific neutrophil and monocyte patterns are linked to early scar formation after a heart attack in STEMI patients.

  Recruiting Shanghai 10th People's Hospital · Shanghai · NCT07764588

• Remote Balance in Everyday Life for young MI patients with distress

  This study tests a remote 6-session program (rBEL) to help adults under 55 who had a heart attack and feel distressed see if the program and study procedures are feasible.

  Recruiting Uppsala University · Uppsala · NCT07706816

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.